Allergy to Gibberellin-Regulated Proteins (Peamaclein) in Children
Autor: | Lucrezia Sarti, Francesca Mori, Mattia Giovannini, Francesco Citera, Leonardo Tomei, Benedetta Biagioni, Claudia Valleriani, Giulia Liccioli, Simona Barni |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
medicine.medical_specialty Allergy Adolescent Immunology Allergic condition Cross Reactions Immunoglobulin E Culprit Allergy Unit Food allergy Clinical Decision Rules Internal medicine medicine Humans Immunology and Allergy Child Sensitization Plant Proteins Retrospective Studies Skin Tests Prunus persica biology business.industry General Medicine European population Allergens Antigens Plant medicine.disease Gibberellins medicine.anatomical_structure Child Preschool Fruit biology.protein Pollen Female business Algorithms Biomarkers Food Hypersensitivity |
Zdroj: | International Archives of Allergy and Immunology. 182:1194-1199 |
ISSN: | 1423-0097 1018-2438 |
DOI: | 10.1159/000517413 |
Popis: | Background: Gibberellin-regulated proteins (GRPs, Peamaclein) are allergens recently identified in plant-derived food allergy (FA), and little is known about the clinical manifestations of this allergic condition in the European population, especially in children. Objective: Our study aimed to identify and characterize pediatric patients with pollen-FA due to GRP sensitization. Methods: We retrospectively analyzed the charts of patients referred to the Allergy Unit of the Meyer Children’s Hospital in Florence for suspected FA. Three main eligibility criteria based on the actual knowledge of GRP allergy were used to select patients deserving further investigations: (1) systemic reactions after consumption of fruit or an unknown culprit food, (2) positive skin prick tests to both cypress pollen and Pru p 3-enriched peach peel extracts, (3) negative in vitro test results for Pru p 3 serum-specific Immunoglobulin E (sIgE). We performed the in vitro test to determine the anti-rPru p 7 (Peamaclein) sIgE levels in the selected patients. Results: We identified 10 pediatric patients with Pru p 7 allergy and described their characteristics. The use of our eligibility criteria showed a high accuracy in identifying these patients: 100% of the selected patients had positive in vitro results for Pru p 7. We therefore proposed a diagnostic algorithm for Pru p 7 allergy. Conclusion: This is the first case series of European pediatric patients with a demonstrated Peamaclein allergy. These findings broaden our knowledge on GRP allergy in pediatric populations and could help clinicians to suspect, diagnose, and manage this recently discovered plant-derived FA. |
Databáze: | OpenAIRE |
Externí odkaz: |